RPTX NASDAQ
Montreal, QC H4S 2A1
CA
Repare Therapeutics Inc., a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies that focuses on genomic instability, including DNA damage repair. Its lead product candidate is RP-3500, an oral small molecule inhibitor for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing RP-6306, which is under Phase I clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; and Polymerase Theta program, a SL target associated with BRCA mutations and other genomic alterations. The company was incorporated in 2016 and is headquartered in Montreal, Canada.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| BVF PARTNERS L P/IL | U-Tender | 548,938 | $2.20 | 2026-01-28 |
| SCHAFER CAROL | D-Return | 37,941 | $2.06 | 2026-01-28 |
| SCHAFER CAROL | D-Return | 8,000 | $2.20 | 2026-01-28 |
| RHOADS ANN D | D-Return | 4,000 | $2.20 | 2026-01-28 |
| Civik Thomas | D-Return | 7,500 | $2.20 | 2026-01-28 |